Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2012

View Archived Issues

Frontier Biotechnologies presents early clinical data for albuvirtide

Cubist Pharmaceuticals presents novel, broad-spectrum cephalosporin

New peptidase inhibitors patented by GlaxoSmithKline

Actelion Pharmaceuticals presents novel orexin receptor antagonists

New GPR119 receptor agonists patented by LG Life Sciences

Amgen synthesizes novel BACE inhibitors

Czech group presents novel NMDA receptor antagonists

Bristol-Myers Squibb discloses new HCV inhibitors

Results reported from phase II studies of BI-671800 in adult asthma

Hybrigenics begins phase II trial of oral inecalcitol in CLL

Immunetics awarded NIH contract for blood screening test

Galapagos presents promising in vivo results for GLPG-0492

Osmotica Pharmaceutical and Panacea Biotec form strategic alliance

e-Therapeutics begins second phase I trial of ETS-2101 in cancer

ReNeuron files two U.K. clinical trial applications and updates stem cell therapy pipeline

Oncolytics modifies phase III study of Reolysin

Visterra and Pfizer to collaborate on novel antibody discovery

KaloBios begins phase II study of MAb for asthma

Topline phase III data reported for rifamycin SV MMX

Healthpoint Biotherapeutics begins phase III trial for venous leg ulcers

FDA approves Genzyme's MS therapeutic

First launch of Eisai's antiepileptic agent announced in Europe

FDA accepts Otsuka's NDA resubmission

Sunesis plans to increase sample size in pivotal VALOR trial

Mitsubishi Tanabe seeks Japanese approval for Maintate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.